Work

Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012

Year: 2011

Type: article

Source: Bioorganic & Medicinal Chemistry Letters

DOI: 10.1016/j.bmcl.2011.11.110

Authors: Bruce J. Melancon, Alexander P. Lamers, Thomas M. Bridges, Gary A. Sulikowski, Thomas J. Utley, Douglas J. Sheffler, Meredith J. Noetzel, Ryan D. Morrison, J. Scott Daniels, Colleen M. Niswender, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley, Michael R. Wood

Institutions: Vanderbilt University, Vanderbilt University Medical Center, United States Department of Veterans Affairs, VA Tennessee Valley Healthcare System

Language: English

Topic: Receptor Mechanisms and Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke

Awards: G2471675597, G2478413624, The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, G574656479, Udall Parkinson's Disease Center at Emory University: Circuitry to Therapy

OpenAlex ID: W2057181663

FWCI: 0.353

Cites: 19

Cited by: 8

Related to: 10